LEXINGTON, KY--(Marketwired - September 24, 2013) - Coldstream
Laboratories, Inc., a provider of sterile drug product development
services, has announced that they have been awarded a 5-year contract with the National Cancer Institute ("NCI") under solicitation number N02CM37007-11 (contract# HHSN261201300031I) entitled "Development and Production of Parenteral Dosage Forms for Clinical Studies."
The contract lasts for five years with the objective of developing and producing pharmaceutically acceptable parenteral dosage forms of cancer drugs for human use. Certain lead agents selected by the NCI will be assigned for development and production as parenteral products. The NCI has been a leader in field of cancer research since its establishment in 1937.
"The requirements for this program mesh perfectly with Coldstream's capabilities and facilities. We couldn't be more pleased to be awarded this opportunity to work with the NCI," said Eric W. Smart, Coldstream's President and Chief Executive Officer. "We work hard to ensure the highest degree of quality in everything we do and being awarded this contract indicates that we are succeeding. Being awarded this contract affords Coldstream the opportunity to continue to make an impact in the field of cancer research and help advance oncologic care for the millions of people impacted by cancer every year."
Coldstream Laboratories, Inc., based in Lexington, KY, is a privately held specialty pharmaceutical contract manufacturing organization. The company was formed in 2007 as a spin-off from the University of Kentucky's Center for Pharmaceutical Sciences and Technology. Coldstream operates Kentucky's only parenteral manufacturing facility.
For more information, visit www.coldstreamlabs.com or email email@example.com.